ECSP10010729A - Péptidos dirigidos a crkl - Google Patents

Péptidos dirigidos a crkl

Info

Publication number
ECSP10010729A
ECSP10010729A EC2010010729A ECSP10010729A ECSP10010729A EC SP10010729 A ECSP10010729 A EC SP10010729A EC 2010010729 A EC2010010729 A EC 2010010729A EC SP10010729 A ECSP10010729 A EC SP10010729A EC SP10010729 A ECSP10010729 A EC SP10010729A
Authority
EC
Ecuador
Prior art keywords
crkl
molecule
peptides directed
peptides
targeting
Prior art date
Application number
EC2010010729A
Other languages
English (en)
Inventor
Wadih Arap
Paul Mintz
Renata Pasqualini
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of ECSP10010729A publication Critical patent/ECSP10010729A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan métodos y composiciones que se dirijan selectivamente a la CRKL a través del uso de péptidos dirigidos a esta molécula. El direccionamiento selectivo hacia la CRKL secretada a través del uso de un péptido dirigido a dicha molécula, puede usarse, por ejemplo, en el tratamiento del cáncer para administrar un compuesto quimioterapéutico, una proteína de fusión, o un constructo de fusión a una célula o tejido canceroso.
EC2010010729A 2008-06-20 2010-12-29 Péptidos dirigidos a crkl ECSP10010729A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7442308P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
ECSP10010729A true ECSP10010729A (es) 2011-04-29

Family

ID=41434721

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010729A ECSP10010729A (es) 2008-06-20 2010-12-29 Péptidos dirigidos a crkl

Country Status (14)

Country Link
US (1) US20110189095A1 (es)
EP (1) EP2303913A4 (es)
JP (1) JP2011525491A (es)
CN (1) CN102105487A (es)
BR (1) BRPI0915718A2 (es)
CA (1) CA2728763A1 (es)
CL (1) CL2010001498A1 (es)
CO (1) CO6331291A2 (es)
CR (1) CR20110034A (es)
EC (1) ECSP10010729A (es)
IL (1) IL210053A0 (es)
MX (1) MX2010014173A (es)
PE (1) PE20110309A1 (es)
WO (1) WO2009155556A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101870734B (zh) * 2010-05-25 2012-06-20 北京大学 一种抑制新生血管生成的融合多肽及其编码基因与应用
CU23950B1 (es) * 2011-03-21 2013-10-29 Ct De Ingeniería Genética Y Biotecnología Péptidos cíclicos con actividad antineoplásica y antiangiogénica
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
KR20160031551A (ko) * 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
MX2016001021A (es) * 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
EP3024846A1 (en) * 2013-07-25 2016-06-01 Novartis AG Cyclic apelin derivatives for the treatment of heart failure
CN104250287B (zh) * 2013-09-11 2017-03-22 中山大学附属肿瘤医院 肿瘤靶向多肽及应用
US10130650B2 (en) 2014-01-27 2018-11-20 The Children's Hospital Of Philadelphia Compositions and methods for treating autoimmune and inflammatory diseases
CN108303539B (zh) * 2018-01-31 2020-08-11 刘双萍 一种乳腺癌细胞检测生物试剂及应用
CN110025577B (zh) * 2019-03-19 2021-09-07 广东药科大学 一种多肽药物口服靶向系统M27-39@FA-MCNs复合体及其制备方法和应用
CN109908369B (zh) * 2019-04-28 2022-02-11 复旦大学附属金山医院 一种新的环状RNA circCRKL在前列腺癌治疗中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667981A (en) * 1994-05-13 1997-09-16 Childrens Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
CA2496938A1 (en) * 2002-08-30 2004-03-11 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2005307789A1 (en) * 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
WO2009091518A2 (en) * 2008-01-15 2009-07-23 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgenic plant with enhanced agronomic traits

Also Published As

Publication number Publication date
BRPI0915718A2 (pt) 2017-06-20
MX2010014173A (es) 2011-06-20
CA2728763A1 (en) 2009-12-23
WO2009155556A3 (en) 2010-04-08
JP2011525491A (ja) 2011-09-22
CN102105487A (zh) 2011-06-22
US20110189095A1 (en) 2011-08-04
CL2010001498A1 (es) 2011-05-20
CO6331291A2 (es) 2011-10-20
WO2009155556A2 (en) 2009-12-23
PE20110309A1 (es) 2011-06-19
IL210053A0 (en) 2011-02-28
EP2303913A2 (en) 2011-04-06
EP2303913A4 (en) 2013-07-24
CR20110034A (es) 2011-06-24

Similar Documents

Publication Publication Date Title
ECSP10010729A (es) Péptidos dirigidos a crkl
CL2016001405A1 (es) A peptide mixture
BR112013003823A2 (pt) conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados
PE20140382A1 (es) Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
CL2008000785A1 (es) Compuestos derivados de 4-((7,7-difluoro-5-metil-6-oxo-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-il)amino)-3-metoxibenzamida; compuesto intermediario; composicion farmaceutica, utiles para tratar el cancer.
WO2008045976A3 (en) Compositions and methods for treating and diagnosing cancers
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
CR20110221A (es) Terapia de combinación con péptidos epoxicetonas peptídicas
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
UY30492A1 (es) Anticuerpo antagonista para el tratamiento del cancer
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
CR20110553A (es) Terapia complementaria contra el cáncer
NI201200134A (es) Polipéptidos agonistas que se enlazan a dr5
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos